Xiaohui Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xiaohui Pan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ling Ding
Department of Biotechnology and Biomedicine, Technical University of Denmark
3 shared publications - Bo Yang
Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
2 shared publications Fengming Luan
Department of Gastrointestinal Surgery, Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou 310009, China
2 shared publicationsHonghai Wu
Zhejiang Province Key Laboratory of Anti‐cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences Zhejiang University Hangzhou China
2 shared publications- Honghai Wu
Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
2 shared publications Hongjie Guo
Zhejiang Province Key Laboratory of Anti‐cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences Zhejiang University Hangzhou China
2 shared publications
Latest Publications
- Open Access
- 2 September 2023
- Published by Wiley in Molecular Oncology
- Vol. 17 (12) , 2659-2674
KLF12 transcriptionally regulates PD‐L1 expression in non‐small cell lung cancer
Recent studies have pointed to the role of Krüpple‐like factor 12 (KLF12) in cancer‐associated processes, including cancer proliferation, apoptosis, and metastasis. However, the role of KLF12 in tumor immunity remains obscure. Here, we found that KLF12 expression was significantly higher in non‐small cell lung cancer (NSCLC) cells with higher programmed death‐ligand 1 (PD‐L1) expression. Additionally, a positive correlation between KLF12 and PD‐L1 was observed in clinical patient tumor tissues. By chromatin immunoprecipitation (ChIP) analysis, KLF12 was identified to bind to the CACCC motif of the PD‐L1 promoter. Overexpression of KLF12 promoted PD‐L1 transcription, whereas silencing of KLF12 inhibited PD‐L1 transcription. Furthermore, signal transducer and activator of transcription 1 (STAT1)‐ and STAT3‐triggered PD‐L1 transcription was abolished in the absence of KLF12, and KLF12 knockdown weakened the binding of STAT1 and STAT3 to the PD‐L1 promoter. Mechanistically, KLF12 physically interacted with P300, a histone acetyltransferase. In addition, KLF12 silencing reduced P300 binding to the PD‐L1 promoter, which subsequently caused decreased acetylation of histone H3. PD‐L1 transcription driven by KLF12 overexpression was eliminated by EP300 silencing. In immunocompetent mice, KLF12 knockout inhibited tumor growth and promoted infiltration of CD8+ T cells. However, this phenomenon was not observed in immunodeficient mice. Overall, this study reveals KLF12‐mediated transcriptional regulation of PD‐L1 in NSCLC; targeting KLF12 may be a potential therapeutic strategy for NSCLC.
- 2 September 2023
- Published by Wiley in Molecular Oncology
- Vol. 17 (12) , 2659-2674
Open AccessKLF12 transcriptionally regulates PD‐L1 expression in non‐small cell lung cancer
Recent studies have pointed to the role of Krüpple‐like factor 12 (KLF12) in cancer‐associated processes, including cancer proliferation, apoptosis, and metastasis. However, the role of KLF12 in tumor immunity remains obscure. Here, we found that KLF12 expression was significantly higher in non‐small cell lung cancer (NSCLC) cells with higher programmed death‐ligand 1 (PD‐L1) expression. Additionally, a positive correlation between KLF12 and PD‐L1 was observed in clinical patient tumor tissues. By chromatin immunoprecipitation (ChIP) analysis, KLF12 was identified to bind to the CACCC motif of the PD‐L1 promoter. Overexpression of KLF12 promoted PD‐L1 transcription, whereas silencing of KLF12 inhibited PD‐L1 transcription. Furthermore, signal transducer and activator of transcription 1 (STAT1)‐ and STAT3‐triggered PD‐L1 transcription was abolished in the absence of KLF12, and KLF12 knockdown weakened the binding of STAT1 and STAT3 to the PD‐L1 promoter. Mechanistically, KLF12 physically interacted with P300, a histone acetyltransferase. In addition, KLF12 silencing reduced P300 binding to the PD‐L1 promoter, which subsequently caused decreased acetylation of histone H3. PD‐L1 transcription driven by KLF12 overexpression was eliminated by EP300 silencing. In immunocompetent mice, KLF12 knockout inhibited tumor growth and promoted infiltration of CD8+ T cells. However, this phenomenon was not observed in immunodeficient mice. Overall, this study reveals KLF12‐mediated transcriptional regulation of PD‐L1 in NSCLC; targeting KLF12 may be a potential therapeutic strategy for NSCLC.
- Open Access
- 28 July 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (10) , 4337
Author correction to ‘Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA’ [Acta Pharmaceutica Sinica B 13 (2023) 2585–2600]
- 28 July 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (10) , 4337
Open AccessAuthor correction to ‘Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA’ [Acta Pharmaceutica Sinica B 13 (2023) 2585–2600]
- 16 May 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 213, 115596
Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists
- 16 May 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 213, 115596
Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists
- Open Access
- 17 April 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (6) , 2585-2600
Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
- 17 April 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (6) , 2585-2600
Open AccessMevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
- Open Access
- 22 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
ICT1 Promotes Osteosarcoma Cell Proliferation and Inhibits Apoptosis via STAT3/BCL‐2 Pathway
Osteosarcoma (OS) is a familiar malignant bone tumor that occurs mainly in adolescents. Immature colon carcinoma transcript‐1 (ICT1) is an important member of the large mitoribosomal subunit in mitochondrial ribosomes, which has been shown to be closely related to tumorigenesis. Its expression and function in OS, however, remained unclear. Here, we showed that ICT1 was significantly upregulated in OS and promoted the growth of OS cells. Mechanistically, ICT1 acted as an oncogene in OS and promoted proliferation and inhibited apoptosis of OS cells through the STAT3/BCL‐2 axis. These results reveal a novel insight into the role of the ICT1/STAT3/BCL‐2 axis in OS and therefore may represent a novel molecular target for novel treatments.
- 22 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessICT1 Promotes Osteosarcoma Cell Proliferation and Inhibits Apoptosis via STAT3/BCL‐2 Pathway
Osteosarcoma (OS) is a familiar malignant bone tumor that occurs mainly in adolescents. Immature colon carcinoma transcript‐1 (ICT1) is an important member of the large mitoribosomal subunit in mitochondrial ribosomes, which has been shown to be closely related to tumorigenesis. Its expression and function in OS, however, remained unclear. Here, we showed that ICT1 was significantly upregulated in OS and promoted the growth of OS cells. Mechanistically, ICT1 acted as an oncogene in OS and promoted proliferation and inhibited apoptosis of OS cells through the STAT3/BCL‐2 axis. These results reveal a novel insight into the role of the ICT1/STAT3/BCL‐2 axis in OS and therefore may represent a novel molecular target for novel treatments.
- Open Access
- 18 September 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (5) , 5193-5199
The role of aplysia ras homolog I in colon cancer cell invasion and adhesion
Aplysia ras homolog I (ARHI) acts as a tumor suppressor in certain cancer cells. However, the role of ARHI in colon cancer development has not previously been reported. The present study aimed to investigate the functional role of ARHI in colon cancer focusing on the aspect of metastasis. Furthermore, the molecular mechanism underlying its function was explored. The present study detected the expression of ARHI in a human colon epithelial cell line and colon cancer cell lines using reverse transcription‑quantitative polymerase chain reaction and western blotting analysis. It was demonstrated that ARHI expression was significantly downregulated in colon cancer cell lines compared with the normal colon epithelial cell line (P<0.05). An ARHI‑pcDNA3.1 plasmid was transfected into HCT116 cells to overexpress ARHI. The number of invaded cells and the adhesive ability were significantly decreased in the ARHI overexpression group compared with the control group, as determined by cell invasion and adhesion assays (P<0.05). Furthermore, ARHI overexpression led to increased mRNA and protein expression levels of E‑cadherin, and decreased mRNA and protein expression levels of N‑cadherin and vimentin. Wnt/β‑catenin signaling was suppressed in HCT116 cells overexpressing ARHI. Lithium chloride, a wnt/β‑catenin signaling activator, was able to attenuate the effect of ARHI on HCT116 cell invasion and adhesion. In addition, the effect of ARHI on epithelial‑mesenchymal transition (EMT) in HCT116 cells was reversed by the activation of wnt/β‑catenin signaling. In conclusion, the present study provided novel evidence that ARHI could inhibit colon cancer cell invasion and adhesion through suppressing EMT, and these effects were achieved, at least partially, via the suppression of the wnt/β‑catenin signaling pathway. The present findings may help in developing novel therapeutic approaches for colon cancer.
- 18 September 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 14 (5) , 5193-5199
Open AccessThe role of aplysia ras homolog I in colon cancer cell invasion and adhesion
Aplysia ras homolog I (ARHI) acts as a tumor suppressor in certain cancer cells. However, the role of ARHI in colon cancer development has not previously been reported. The present study aimed to investigate the functional role of ARHI in colon cancer focusing on the aspect of metastasis. Furthermore, the molecular mechanism underlying its function was explored. The present study detected the expression of ARHI in a human colon epithelial cell line and colon cancer cell lines using reverse transcription‑quantitative polymerase chain reaction and western blotting analysis. It was demonstrated that ARHI expression was significantly downregulated in colon cancer cell lines compared with the normal colon epithelial cell line (P<0.05). An ARHI‑pcDNA3.1 plasmid was transfected into HCT116 cells to overexpress ARHI. The number of invaded cells and the adhesive ability were significantly decreased in the ARHI overexpression group compared with the control group, as determined by cell invasion and adhesion assays (P<0.05). Furthermore, ARHI overexpression led to increased mRNA and protein expression levels of E‑cadherin, and decreased mRNA and protein expression levels of N‑cadherin and vimentin. Wnt/β‑catenin signaling was suppressed in HCT116 cells overexpressing ARHI. Lithium chloride, a wnt/β‑catenin signaling activator, was able to attenuate the effect of ARHI on HCT116 cell invasion and adhesion. In addition, the effect of ARHI on epithelial‑mesenchymal transition (EMT) in HCT116 cells was reversed by the activation of wnt/β‑catenin signaling. In conclusion, the present study provided novel evidence that ARHI could inhibit colon cancer cell invasion and adhesion through suppressing EMT, and these effects were achieved, at least partially, via the suppression of the wnt/β‑catenin signaling pathway. The present findings may help in developing novel therapeutic approaches for colon cancer.